We speculate that in the absence of any natural antagonists, the refractory behaviour exhibited by TGF-β after stimulation may be a defence against deregulated signalling, such as occurs in cancer and fibrosis (Akhurst and Hata, 2012). This evidence concerns the gene TGFB1 and cancer.